Mostra el registre parcial de l'element
dc.contributor.author | Georgakopoulou, Eleni A. | es |
dc.contributor.author | Loumou, Panagiota | es |
dc.contributor.author | Grigoraki, Aikaterini | es |
dc.contributor.author | Panagiotopoulos, Antonios | es |
dc.date.accessioned | 2023-06-16T08:36:40Z | |
dc.date.available | 2023-06-16T08:36:40Z | |
dc.date.issued | 2021 | es |
dc.identifier.citation | Georgakopoulou, E., Loumou, P., Grigoraki, A., & Panagiotopoulos, A. (2021). Isolated lip dermatitis (atopic cheilitis), successfully treated with topical tacrolimus 0.03%. En Medicina Oral Patología Oral y Cirugia Bucal (pp. e357-e360). Medicina Oral, S.L. https://doi.org/10.4317/medoral.24230 | es |
dc.identifier.uri | https://hdl.handle.net/10550/88032 | |
dc.description.abstract | Exfoliative and erosive cheilitis, may be a source of speech and chewing discomfort, but may also be an aesthetic issue for the patients affected. Such a clinical presentation may implicate a variety of inflammatory conditions, including atopic (eczematous) cheilitis. Topical and systemic agents, e.g. corticosteroids, have been used to treat inflammatory lip conditions. Topical tacrolimus has also been used in some inflammatory lip conditions. We performed a retrospective clinical analysis of atopic cheilitis patients. Between 2015 and 2020, we addressed 7 (seven) patients with atopic dermatitis affecting only lips and were diagnosed as atopic-eczematous cheilitis. They were treated with 0.03 per cent topical tacrolimus ointment and responded completely. These cases represent an underreported atopy / eczema event;-few cases of atopic cheilitis without concomitant dermal lesions appear in the literature. We are also showing and discussing yet another application of tacrolimus in a local atopic form of inflammation affecting the lips. | es |
dc.subject | osseodensification | es |
dc.subject | primary stability | es |
dc.subject | low density bone | es |
dc.subject | rfa | es |
dc.title | Isolated lip dermatitis (atopic cheilitis), successfully treated with topical tacrolimus 0.03% | es |
dc.type | journal article | es_ES |
dc.subject.unesco | UNESCO:CIENCIAS MÉDICAS | es |
dc.identifier.doi | 10.4317/medoral.24230 | es |
dc.type.hasVersion | VoR | es_ES |
dc.identifier.url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141307/ |